Julie M. Vose

TL;DR: After alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the allo BSCT setting, are suggested.

TL;DR: The important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL, are highlighted.

TL;DR: Predictive miRNA biomarker signatures in DLBCL are identified, including high expression of miR-155, which is significantly associated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment failure, suggesting a novel treatment option for resistantDLBCL.

TL;DR: Results show that Hh signaling is important in the pathogenesis of B-CLL and, hence, may be a potential therapeutic target, and selective down-regulation of GLI1 by antisense oligodeoxynucleotides (GLI1-ASO) results in decreased BCL2 expression and cell survival, suggesting that GLI 1 may regulate BCL 2 and, thereby, modulate cell survival in B- CLL.

TL;DR: A phase III diagnostic accuracy study to test the ability of gene expression profiles (GEPs; index test) to identify PTCL subtype supports the usage of an MC as additional tool in the diagnostic workup of nodal P TCL.